Drug Profile
Research programme: NSAC compounds - Helsinn Therapeutics
Alternative Names: NSACLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Developer Helsinn Therapeutics
- Class Small molecules
- Mechanism of Action Ghrelin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Phase Unknown Unspecified
- No development reported Bone resorption; Fracture; Metabolic disorders; Muscular atrophy
Most Recent Events
- 18 May 2006 No development reported - Preclinical for Bone resorption in USA (unspecified route)
- 18 May 2006 No development reported - Preclinical for Fracture in USA (unspecified route)
- 18 May 2006 No development reported - Preclinical for Metabolic disorders in USA (unspecified route)